AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
News|Articles|August 2, 2004
- Pharmaceutical Technology-08-02-2004
- Volume 28
- Issue 8
Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolates
Author(s)Robert R. Reich
The authors examine the VHP resistance of microbial isolates recovered from controlled environments and compared them with commercially available biological indicators under various test conditions.
Articles in this issue
about 22 years ago
Stable Isotopic Characterization of Analgesic Drugsabout 22 years ago
August 2004about 22 years ago
Increased Outsourcing Driving Investments in CRO Industryabout 22 years ago
E-Health Information Campaign Shapes Pharmaceutical Regulationabout 22 years ago
In the Spotlight-August 2004about 22 years ago
Interphex Delivers Packaging Solutionsabout 22 years ago
Decoding the US PharmacopeiaRelated to this article
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
3
Three Targeted Delivery Deals: What CMC Teams Should Watch
4
Expedited IND Pilot Targets Sequential Delays Slowing First-in-Human Trials
5